TYRA — Tyra Biosciences Cashflow Statement
0.000.00%
- $840.11m
- $457.65m
- 41
- 32
- 59
- 40
Annual cashflow statement for Tyra Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-Q | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -4.07 | -9.34 | -26.3 | -55.3 | -69.1 |
Depreciation | |||||
Non-Cash Items | 0.934 | 0.454 | 2.89 | 10.6 | 12.3 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.505 | 1.07 | -0.481 | -5.85 | 6.36 |
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -2.62 | -7.76 | -23.7 | -50.3 | -50.1 |
Capital Expenditures | -0.02 | -0.312 | -0.661 | -0.559 | -0.77 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | 0.016 | 0 | -144 |
Sale of Fixed Assets | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.02 | -0.312 | -0.645 | -0.559 | -145 |
Financing Cash Flow Items | 0.165 | — | -0.025 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.157 | 23.4 | 311 | 0.632 | 1.54 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -2.48 | 15.4 | 287 | -50.2 | -193 |